Analyzing AIM ImmunoTech (NYSE:AIM) & Caribou Biosciences (NASDAQ:CRBU)

Caribou Biosciences (NASDAQ:CRBU) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Valuation & Earnings

This table compares Caribou Biosciences and AIM ImmunoTech”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.48 million	15.94	-$102.07 million	($1.65)	-1.22
AIM ImmunoTech	$200,000.00	66.93	-$28.96 million	($0.47)	-0.45

AIM ImmunoTech has lower revenue, but higher earnings than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Caribou Biosciences and AIM ImmunoTech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,290.81%	-45.46%	-38.07%
AIM ImmunoTech	-12,594.21%	-421.73%	-147.54%

Volatility & Risk

Caribou Biosciences has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.36, indicating that its share price is 136% less volatile than the S&P 500.

Institutional and Insider Ownership

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are held by institutional investors. 9.5% of Caribou Biosciences shares are held by company insiders. Comparatively, 0.0% of AIM ImmunoTech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Caribou Biosciences and AIM ImmunoTech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	0	0	3	0	3.00
AIM ImmunoTech	0	0	2	0	3.00

Caribou Biosciences currently has a consensus target price of $11.25, suggesting a potential upside of 456.93%. AIM ImmunoTech has a consensus target price of $3.00, suggesting a potential upside of 1,327.89%. Given AIM ImmunoTech’s higher probable upside, analysts clearly believe AIM ImmunoTech is more favorable than Caribou Biosciences.

Summary

Caribou Biosciences beats AIM ImmunoTech on 8 of the 13 factors compared between the two stocks.

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

About AIM ImmunoTech

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.